Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce, further to its announcement on 8 September 2016, that the abstract and poster relating to the results of its preclinical study of SFX-01 in various models of the relapsing remitting form of multiple sclerosis are now available on the Company’s website.
The preclinical study focused on the comparison of SFX-01 with dimethyl fumarate, the active principle in BG-12, which is marketed as Tecfidera®.
In addition to this completed preclinical study, Evgen Pharma has ongoing clinical studies of SFX-01. A Phase II study in subarachnoid haemorrhage is currently underway and the first patient is expected to be dosed shortly in a Phase II study in breast cancer.
The preclinical study data in multiple sclerosis are being presented this week in London at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
The poster, entitledEfficacy of SFX-01, a sulforaphane-based drug in experimental autoimmune encephalomyelitis, is available at this link: https://buchanan.enablecloud.co.uk/index.php?entryPoint=campaign_trackerv2&track=ced146ac-7b09-11e6-acdb-18a905591bc2&identifier=55a0af2e-7b0a-11e6-bfe8-001a4bbe9414
The abstract of the poster is at this link: https://buchanan.enablecloud.co.uk/index.php?entryPoint=campaign_trackerv2&track=ced146ac-7b09-11e6-acdb-18a905591bc2&identifier=55a0af2e-7b0a-11e6-bfe8-001a4bbe9414
As stated in the announcement on 8 September 2016, the Company is conducting a commercial appraisal of the potential of SFX-01 in multiple sclerosis and will give a further update to shareholders later this year.
Evgen Pharma plc
Dr Stephen Franklin, CEO
c/o +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
+44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)
John Howes, Rob Rees (Corporate Broking)Editor's Details
Last updated on: 16/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.